Prabotulinumtoxin a
As of the edition of 20 October 2026, Prabotulinumtoxin a is a drug: marketed, first approved in 2018 (CA); acts on SNAP25; US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Unknown
- Brand name
- Jeuveau
- First approved
- 16 August 2018 (CA)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Evolus
- Registered trials
- 17, 1 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Mental health; Mouth and teeth
US protection
US protection ends in 2031.
US protection ends in 2031, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Evolus. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | P60880 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 3 | 0 | 0 |
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 7 | 6 | 0 | 1 |
| Phase 3 | 3 | 2 | 1 | 0 |
| Phase 4 | 2 | 0 | 1 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Evolus | Applicant and Lead sponsor of trials | 2014 to now |